|Home · Cleanses · Food · Supps · Drugs · Tools · Clinics · Refs · Links · BBS · Contact|
This page deals with drugs used to treat cancer. My definition of a drug is any substance that needs to be injected or taken with a doctor's supervision because unskilled use is likely to harm you or conflict with another treatment. Please do consult your doctor about all drugs. If your doctor acts like a jerk about it, stand up to him and tell him it is his responsibility to guide you in the use of the drugs and prevent you from harming yourself, NOT to give you a hard time because the therapy might not work. Remember that you are likely to know more about alternative treatments than your doctor does and that is hard for them to tolerate. Doctors are usually pompous and disdainful when you tell them what therapy you want to use and they did not advise it. In such cases you are dealing with their egos and NOT with their genuine competence-based desire to make you well. Stand up to your doctor and if he does not comply intelligently, go to another doctor.See the DANGERS and USELESSNESS of CHEMOTHERAPY HERE.
Drugs Established as Human Carcinogens
|Radioactive Drugs (phosphorous, radium, mesothorium, thorium dioxide)||Organs where concentrated (acute leukemia, osteosarcoma, nasal sinus carcinoma, angio-sarcoma of the liver)|
|Phenacetin-containing Drugs||Renal Pelvis Carcinoma, Bladder Cancer (?)|
|Alkylating Agents (melphalan, cyclophosphamide, chloroambucil, dihydroxybusulfan and others)||Acute Nonlymphocytic Leukemia, Bladder (cyclophosphamide), Other Sites (?)|
|Immunosuppressive Agents (Azathioprine)||Lymphoma , Skin Cancer, Soft Tissue Carcinoma, Melanoma (?), Liver and Gall Bladder (?), Lung Adenocarcinoma (?)|
|Androgen-anabolic Steriods||Hepatocellular Carcinoma|
Postnatal (DES, conjugated estrogens, oral contraceptives)
Endometrial Carcinoma, Breast Cancer (?), Cervical Cancer (?), Ovarian Cancer (?), Choriocarcinoma (?), Melanoma (?), Liver Tumors (benign)
Aids Drugs List
Click HERE to see a list of drugs and other terminology relating to AIDs.
John Stacy Roberts may have discovered "THE" cure for cancer. Read all about it in his writeup on Thiazolidine-4-Carboxylic Acid. Also, the following message is from John Roberts to all anti-cancer practitioners:
Date: Sun, 11 Dec 2005 05:09:37 -0600
Subject: Cancer cure?/Penicillin/Mushrooms
Medline is www.ncbi.nlm.nih.gov/pubmed ; type in the number or CAPITALIZED WORDS to see the article.
Tac (Thiazolidine-4-carboxylic acid) caused the "...disappearance of evidence of cancer." (Medline 6101417)
Tac is related to Penicillin; few researchers in medicine are aware of this fact.
Type THIAZOLIDINE-4-CARBOXYLIC ACID PENICILLIN into Medline, and you will see "No items found."
Type the same words into Google, and you will see 284 items (as of 12/11/2005).
Tac constitutes 13% (133.18/1056.5) of RC-3950-II
The Cure for Cancer? http://cancercure.ws/tac-cure.htm , pages 1 and 2 and Medline 7809097, Table 1. item 2.
Medline 9012839 - Focus on Table 1., items B3 (which is RC-3950-II) and AN-257; 2-pyrrolino-DOX is 2-pyrrolinodoxorubicin which is "500-1000 times more potent" (Medline 8637897 & 8692981) than Doxorubicin (DOX) (Adriamycin) ('The Red Devil') which is the most effective, traditional anti-cancer drug presently in use (Medline 1462166).
Note that AN-257 contains B3 (13% Tac); now go to Table 3 and see how many
"times higher" AN-257 was than DOX in causing the
"Inhibition of growth upon these "human cancer cell lines"; divide the DOX numbers by the AN-257
numbers: Pancreatic - 335; SCLC (Small Cell Lung
Cancer) - 1657; Prostate -224; Gastric (Stomach) - 857.
This also might help:
John S. Roberts
"GBE" is a cure for the prostate cancer which afflicts 80% of the men over the age of 80. This treatment was developed by Dr. David Rubin, Medical Director of Co-Enzyme Technology, Ltd. of San Diego, and it is manufactured in Israel. Treatment takes about a month and its effect lasts from 6 months to 4 years. It is primarily effective for Prostate cancer, and it is quickly becoming known as a "cure", not just a treatment. The drugs cost about $1100 (1998 price), and have gone through phase One clinical trials in Mexico. The treatment can be administered by your own doctor if you order it for personal use. After the effect wears off, you can take additional treatments.
The treatment is a three-phase process that works by inducing drugs that metabolize into a poison that kills cancer cells while leaving normal cells alone. It has proven its ability to drop the PSA level of prostate cancer victims to less than ONE during the effective period. It yields a higher quality, longer life, and virtually no unpleasant side effects.
It works like this, according to Dr. Rubin.
Glycosole - A genetic aberration in chromosiome #7 of certain malignant cells, and in DNA mutations elsewhere, cause abnormal biosynthesis of two enzymes: Beta-Glucuronidase and Tyrosinase. Glycosole (Para-Methoxy-Phenyl-Glucoronide, also known as Glucuronide of 4-Hydroxy-Anisole) (PMPG) poisons cancer cells after two sequential activations by those enzymes. Normal body cells are not affected because they do not have these enzymes in them. The liver detoxifies the phenols with Glucuronic acid, catalyzed by U.D.P.-Glucuronyl-Transferase. The Glycosole is hydrolyzed in the cancer cells by the first enzyme (Beta-Glucuronidase) to yield Para-Methoxy-Phenol. Only at the cancer site is the enzyme available to catalyze the reaction, and only there is it membrane-linked, allowing it to be exposed to the Glycosole substrate.
The Para-Methoxy-Phenol (PMP) released from the above reaction is now available as a substrate for the second reaction, catalyzed by the enzyme Tyrosinase. Tyrosinase oxidizes the PMP to a toxic molecule known as Methoxy-Ortho-Benzoquinone (MOB).
MOB is a strong electrophylic molecule, an alkylating agent. It can conjugate sensitive sites on proteins, enzymes, lipids, and nucleic acids. The attacked cancer cell tries to defend itself against this protruder by sacrificing a molecule of Gluthathione as an electron donor, thereby forming a molecule of Mercapturic acid.
The amount of Glutathione in MANY cancer cells is limited, and once it is depleted, the cancer cell cannot defend itself against the oxidizing stress caused by the MOB. This denaturizes the cell. Important Sulphydril groups of different macromolecules are irreversibly conjugated to the MOB and are being destroyed. Also, MOB-DNA adducts are being formed at different nucleophilic sites upon DNA molecules.
Benzylidene-Glucose (BG) - Meanwhle, SOME cancer cells are still capable of producing increased levels of Glutathione, acting to protect those cells from MOB. After being administered orally or intraveinously, the BG is hydrolyzed in the body, yielding Glucose and Benzaldehyde (oxidized by the enzyme Aldehyde dehydrogenase in the liver and other organs into Benzoic acid). This does not happen in most cancer cells, however. In many cancer cells a hetrocyclic molecule (Thiazolidine-4-carboxilic acid is formed between Benzaldehyde and Cysteine (one of Glutathione's structural amino acids). This reaction is irreversible, and it depletes the storage of Cysteine, thereby preventing production of more Glutathione and making the cancer cell defenseless against devastation by MOB. In this case, BG is supplementing the Glycosole in poisoning the cancer cell, but it is also toxic to cancer cells by itself.
Ethacrinic Acid - this is a loop diuretic and potent inhibitor of the enzyme Glutathione-S-Transferase (GST) which catalyzes Mercpturic acid (also formed by the reaction between MOB and Gluthathione). If the BG above does not completely eliminate the synthesis of Gluthathione, the addition of Ethacrinic acid finishes the job of eliminating it by inhibiting that reaction between MOB and Gluthathione and enables further alkylating distraction of the cancer cells.
Conclusion - these three drugs constitute a 3-barrel shotgun effect to destroy cancer cells by poisoning them while remaining non-toxic to normal cells. The first drug poisons the cancer cell, and the other two prevent the cancer cell from neutralizing the effect of the first.
For more information, contact Dr. David RUBIN at Co-Enzyme Technology Ltd, 8949 Montrose Way, San Diego CA 92122, Phone (619) 270-8138, Fax 457-7132 (Laboratory - 4622 Santa Fe Street, San Diego, CA 92109).
MGN3 is a new drug for fighting cancer. Read about it here
According to the American Cancer Society web site (http://www.cancer.org/alt_therapies/overviews/unprpopu.html), Cancell is composed of common chemicals, including nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol. As far as I know, the FDA has never tested Cancell to determine its effectiveness in treating cancer, but many people claim it is very effective. Although the formula of Cancell has changed slightly over the years, it contains: inositol, potassium, sodium, copper, and a bioflavonoids complex. These ingredients are clearly listed on the label.
A main active ingredient is catechol. It inhibits cancer cell respiration, thus causing the cells to drop below their ability to survive, and allowing the body to dispose of them in the normal way dead cells are disposed of. Its only known negative side effect is that it makes you tired when starting on the program.
Avoid sugar, Vitamin C, Vitamin E, Selenium, and C0Q10 when taking Cancell. Noni, grape seed extract, germanium 132, and laetrile work well when taken with Cancell. Willard's Water (that reduces surfase tension of water and makes Cancell more easily absorbable by the body), bromelain (an enzyme from pineapples that fights lysed proteins created by Cancell), and pancreatin (a pancreatic enzyme that strips the protective coating off cancer cells so they can be destroyed) can be taken with Cancell to improve its effectiveness.
In 1990, Mark Waters produced a video about Cancell called At Whose Expense? -The Suppression of a Cancer Cure That Works. The video is 55 minutes long and has interviews with several folks who used Cancell. If you would like a copy e-mail Mark Waters at WatersInk@AOL.com or call Backcountry Productions, Longmont, CO (303) 772-8358
Entelev was developed by a chemist, James Sheridan of Rosell, Michigan. He theorized the possibility of chemically controlling the energy needed by the cells of our body to cause energy low cancer cells to revert to a state where the body can eliminate them as foreign matter. The theory postulates that cancer cells are too energy low to proceed with their normal development. Cancer cells stop their development just short of differentiating into a normal liver, lung, brain ... cell. Sheridan proposed to push cancer cells backward in their development instead of try to encourage them to differentiate.
Sheridan believed he had found a method of controlling the energy available to cells in the early 1930s after witnessing a chemical reaction called rhythmic banding in an analytical chemistry laboratory at Carnegie Tech and reading the Debye Theory, published in 1927 which explores the effects of changing the dielectric constant on reactions of positive and negative ions suggested the means to accomplish this energy reduction.
By 1940, Sheridan had a compound which he tested to be 38% effective. He continued improving the formulation using laboratory animals. Eventually over 20,000 animal experiments were performed and, by 1953 the development stage ended. Currently the HOPE organization, a support group for cancer surfers, estimate the effectiveness of Entelev at 80% for all cancers. They report higher rates on some specific cancers such as brain tumors and effectiveness in children is lower than 80%. This seems to be related to the higher level of growth common in the cells of children.
Sheridan performed some of his development work on Entelev while he worked for the Michigan Cancer Foundation in the 1950's. After performing their own study, they notified the American Cancer Society that Entelev was ready for testing. The American Cancer Society wanted Sheridan to be involved, so they transferred him to their payroll. Within two months, after that transfer was made, Sheridan was fired without even starting the testing.
Based on the animal testing, Sheridan knew that Entelev was non-toxic and started giving it to friends who were at the end of the line. Word spread of the effects it had on these people and Sheridan started receiving requests from all over the country. Unable to refuse to give people a change for life, he began distribution it for free to anyone who asked for it. The FDA eventually placed an injunction against the distribution of Entelev.
Around 1984, a cancer sufferer (who wishes to remain nameless) was given the prognosis of six weeks to live due to advanced cancer. Instead of dying on schedule, he acquired a bottle of Entelev and in six weeks he was declared cancer-free. Unfortunately, Sheridan had recently quit distributing Entelev in response to a court injunction because he had not gained FDA approval. This nameless man had written six technical books, and was competent to understand the formulation so Sheridan give it to him, but he didnt have the equipment for production. Mr. Nameless contacted a friend, Ed Sopcak who is a metallurgist. Sopcak agreed to make it and eventually started working with Sheridan and distributing it for free between 1984 and 1992.
With their own money Sheridan and Sopcak continued to seek FDA approval. The FDA required toxicity testing. Sheridan and Sopcak decided to pay for this testing because they couldnt get help from the drug company influenced cancer agencies. Sheridan found what he considered the best laboratory in the country in New Mexico. The cost of the toxicity test was originally $5,000. After they got the material, they called Jim and said it would cost $7,000. Sheridan and Sopcak still agreed. The cost went to $15,000. Still Sheridan and Sopcak agreed. Then the lab called and said for some reason or other they were unable to do it.
Sheridan drove to the lab and said he would like to have a toxicity test run. They said they could have it done within a week. After hearing that the material was Entelev, everything changed. They absolutely couldn't get around to doing it. This treatment continued for years. Some people would say that the $700 billion a year Chemo industry has something to do about it. Sheridan has retired and no longer pursues the battle.
If you want more info on Cancell, visit the Cancell web site.
Iscador is a derivative of mistletoe and is patented by a Swiss company. It is a known treatment for cancer and is administered in Europe. More on this later.
T-1622 is an ozone-based drug that controls metastasis, or spreading of cancer. The following info was provided by the web site that suggets treatment (reference at the end of this topic).
Metastasis the process by which malignant neoplasms can shed individual cells, which can travel through the lymph vessels or blood vessels, lodge in some distant organ, and grow into tumors in their own right. There are two major routes of metastasis, 1) hematogenous, in which the cells travel through the blood vessels, and 2)lymphogenous, in which the lymphatic vessels conduct the cancer cells. In the case of lymphogenous metastasis, the metastatic tumors can grow from cancers cells entrapped in the lymph nodes that collect the lymph draining from the organ where the original cancer has developed, causing the nodes to enlarge. In the case of breast cancer, the axillary (underarm) nodes are the first to become involved. In the case of cancer of the larynx (voice box), the nodes on either side of the neck (cervical nodes) are first. Hematogenous metastases tend to deposit in the lungs, liver, and brain. Many cancers metastasize both lymphogenously and hematogenously. Most cancer operations attempt to remove not only the cancerous organ, but also the lymph nodes that drain that organ. Some types of cancer, especially the common ones (lung, breast, colon, and prostate cancers) tend to metastasize to lymph nodes first.
The first object of our study was to control Metastasis, in which cells from the tumor, seed out to other parts of the body and then grow to tumors themselves, and/or para neoplastic syndromes, in which the neoplasm secretes metabolic poisons or inappropriately large amounts of hormones that cause problems with functions of various body systems. Biological control was ruled out due to adverse side effects. Leaving chemical control as the only logical choice. After studying numerous compounds, ozonides of terpenes hydrocarbons were studied. Terpenes are widespread in nature, mainly in plants as constituents of essential oils. Many terpenes are hydrocarbons, but oxygen-containing compounds such as alcohols, aldehydes or ketones (terpenoids) are also found. Their building blocks is the hydrocarbon isoprene, CH2=C(CH3)-CH=CH2. Terpene hydrocarbons therefore have molecular formulas (C5H8)n, they are classified according to the number of isoprene units. The ozonized terpenes contain up to 50% oxygen by weight.
T-1622 was designed to control Metastasis, penetrate tumor cells, and inactivate the protoplasm that goes into the cells and feeds the tumor cells. If the nutritional protoplasm is eliminated, the cancer cell starves to death. T-1622 has three oxygen atoms replacing the double bonds at sites of unsaturation, creating trioxyacyclopentane. Thereby creating a highly reactive compound, the O3 as such will not be found in the red blood cell since it is not able to pass the cellular membrane. The red blood cell will react to the peroxide immediately for being a cytotoxin, and will activate its detoxification mechanism through the glutathione system. In order to keep up its system protecting the red blood cell against oxidation, the amount of glutathione consumed must be reproduced, which is done through a bypath of glycolysis, i.e. the pentose phosphate path way (PPW). The main task of the pentose phosphate pathway is to protect the hemoglobin against oxidation into methemoglobin and hence to keep up the function enabling the transmission of Oxygen. In turn, this means that the entire erythrocyte metabolism is stepped up. So that any cells of the tumor will be effectively oxidized and eliminated from the body. This is accomplished with site blocks injections, and IV drip of T-1622.
Penetration of cell tumor was achieved with the addition of a solvent, that had no action on the tumor cell itself, but used as a vehicle, penetrating the tissues to carry T-1622 to the protoplasm thereby inactivating and therefore starved the cancer cells to death. Because of T-1622 alkaline nature, it is tumor specific to the nucleic acid of tumor cells. After prolonged IV drip T-1622 collects in the nucleus of cancer cells. Normal cells have the ability to absorb and transpose T-1622 from there nucleus.
T-1622 has been used for the past two years on breast cancer patients. With a 92% remission rate, by injection only, thereby eliminating surgery. Response to T-1622, by other forms of cancer, are now being studied.
It took over four years to get T-1622 to clinical trials stage with as estimated cost of developing the new drug at $1.5 million to $1.8 million, excluding personnel costs. Further multi-agent randomized trials must still be conducted before the therapy will be approved by the FDA and available for general use in the United States. Chemical companies are also very interested in T-1622 for commercial applications.
Med Care Cancer Institute is also studying other biologic sources of therapeutic agents: enzymes, proteins, and hormones which originate in animal, plants, or humans.
T-1622 is not yet available for general use in the United States. It is administered in Tijuana or Ensanada Mexico by Dr. Frank P. Truitt. Send him email or call (800) 280-0105 to request directions to his clinic, or visit http://www.medcure.com.
Tamoxifen (trade name Nolvadex) is a drug in pill form, taken orally, that interferes with the activity of estrogen (a female hormone). Tamoxifen has been used to treat both advanced and early stage breast cancer. It has been used for nearly 20 years to treat patients with advanced breast cancer. More recently, it also is being used as adjuvant, or additional, therapy following primary treatment for early stage breast cancer.
As of 6 April 1998, six years after its inception, the Breast Cancer Prevention Trial (BCPT) shows a 45 percent reduction in breast cancer incidence among the high-risk participants who took tamoxifen (Nolvadex), a drug used for the past two decades to treat breast cancer. As a result, investigators released the initial study results about 14 months earlier than expected. They also notified the 13,388 women participants of the findings so those women who had been taking the placebo could consider starting tamoxifen therapy after consulting with their personal physicians. Participants will continue to be followed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Pittsburgh-based research network that conducted the trial with support from the National Cancer Institute (NCI).
Some breast cancer cells are ģestrogen sensitive.ī In other words, estrogen binds to these cells and stimulates them to grow and divide. Tamoxifen prevents the binding of estrogen. This stops the cell from growing and in doing so, prevents or delays breast cancer recurrence. Tamoxifen is also known to work through growth factors and the immune system and may provide some benefit even in patients whose tumors are not estrogen sensitive.
Although tamoxifen blocks the effect of estrogen on breast tissue, it acts like a weak estrogen in other body systems. This means that women who take tamoxifen may share some of the beneficial effects of taking estrogen replacement therapy, such as a decreased risk of osteoporosis and a decreased risk of heart disease.
The most common side effect is hot flashes, similar to those experienced during menopause. Tamoxifen may induce menopause in a woman who is close to menopause, however, it rarely does in young women. Other common side effects include vaginal dryness, irregular periods, and weight gain.
In addition, women taking tamoxifen may be at slightly increased risk of developing cataracts. Women who have cataracts before taking tamoxifen may be at slightly increased risk of having eye surgery to remove the cataracts. There has NOT been a generalized decrease in vision in women taking tamoxifen. It is recommended that women taking tamoxifen have eye examinations by an ophthalmologist at least every 2 years.
Many experts believe tamoxifen may increase the risk of uterine cancer. There have been some reports of uterine cancer in women taking tamoxifen. However, the incidence is less than 1% in women taking doses of 20 mg. daily. Most cancer specialists believe that the benefits of tamoxifen outweigh the risk of developing uterine cancer. However, all women using tamoxifen should have regular gynecological exams. New drugs are being released that interfer with estrogen receptor action like tamoxifen does, but have no carcinogenic side effects. Ask your doctor about the latest developments.
Recent research comparing five years of adjuvant tamoxifen therapy with more than five years of tamoxifen has indicated that no additional benefit is obtained from extending the duration of tamoxifen therapy past five years. However, completing five years offers greater benefit than shorter durations of tamoxifen therapy.
Additionally, the medical literature on adjuvant therapy shows benefits as long as 10 to 15 years after starting tamoxifen or 5 to 10 years after stopping it. Considering all the current research data, five years of tamoxifen therapy provides the optimum benefit.
Occasionally, women experience some of the same mood changes with tamoxifen that occur with any hormonal therapy. However, most patients experience no change in their mood as a result of taking tamoxifen.
Despite what you might have heard, the use of tamoxifen for breast cancer prevention is highly controversial. The drug has not been proven to prevent breast cancer. And while its long-term effects on healthy women are unknown, tamoxifen's cancer causing properties are well documented.
Using tamoxifen in cancer patients is one thing; using it in healthy women is another. Tamoxifen is a well-known carcinogen which causes DNA strand breaks. This is an accepted feature of standard chemotherapy where the overriding concern is to keep cancer cells from growing. Carcinogens have not traditionally been an accepted part of preventive medicine, however. The FDA's decisions to allow the sale of tamoxifen and certain cholesterol-lowering drugs (notably the peroxisome inhibitors clofibrate and gemfibrozil) to healthy people marks the first time that drugs with cancer-causing potential have been approved as health enhancements. We believe this marks a dangerous new trend in drug approval.For the full story, see the story in Life Extension Foundation's magazine.
Herceptin(TM) is a breast cancer treatment drug developed by Genentech(trastuzumab) anti-HER2 monoclonal antibody, which is associated with more rapid cancer progression, in women with metastatic breast cancer who overexpress the HER2 oncogene. Herceptin, a humanized HER2 antibody, works by binding to the HER2 growth factor receptors present in excessive amounts on the surface of the cancer cells. This investigational drug offers a new biologic approach for the treatment of HER2 overexpressing metastatic breast cancer, an aggressive form of the disease that affects 25-30 percent of patients. It was announced on 17 December 1997, and phase III clinical trials are delivering favorable results.
Herceptin isthe first treatment created from scientific understanding of the genetic changes that cause cancer. Herceptin is an antibody that attacks cancer cells like a magic bullet. This is the kind of thing that scientists dream about, says Genentechs Dr. Steve Shak. Just to have the opportunity to make such an important difference in this disease is really fantastic, says Shak.
There are limits to the success. Only 30 percent of women with breast cancer are candidates for the drug and in those women it does not always work. But when it does, it often stops the most life-threatening breast cancers. Dr. Dennis Slamon of UCLAs Johnson Cancer Center spent 12 years working on the Herceptin approach often, when many scientists doubted it would ever work. Was he always a believer? Yes, sometimes one of the few believers, Slamon says, laughing. But I was always a believer.
A large, randomized, controlled Phase III trial evaluated the efficacy and safety of adding Herceptin to initial treatment with chemotherapy regimens -- paclitaxel or anthracycline plus cyclophosphamide -- compared to treatment with either of these chemotherapy regimens alone. The study included 469 women with metastatic disease (cancer spread outside the breast) who had not previously been treated with chemotherapy for their metastatic disease. The preliminary analysis of this study indicates that adding Herceptin to chemotherapy did increase the clinical benefit by slowing the progression of the cancer and increasing tumor shrinkage. Further review of cancer progression and tumor shrinkage by an independent Response Evaluation Committee and analysis of response duration, time to treatment failure, quality of life and survival are in progress.
A second, large trial evaluated the efficacy and safety of Herceptin treatment used as a single agent (without chemotherapy) in 222 women with HER2 overexpressing metastatic breast cancer who had relapsed following treatment with one or two prior chemotherapy regimens. A clinical benefit appears to be present in this study as well.
Overall, the most common adverse events related to Herceptin were chills and fever, most often infusion-related. An increased risk of cardiac dysfunction was observed in women treated at the same time with Herceptin and anthracyclines compared to women receiving anthracyclines alone. This syndrome of cardiac dysfunction is similar to that previously observed with anthracycline treatment. This side effect can be potentially severe or life-threatening, and may suggest that some patients should not be treated with the antibody and anthracyclines at the same time. In a limited number of patients, there did not appear to be a large increased risk of cardiac dysfunction in women receiving Herceptin with paclitaxel or Herceptin as a single agent. Detailed analysis of the safety profile is ongoing and will be submitted to the FDA when complete.
Genentech will work with the clinical trial investigators to prepare and submit the final analyses of efficacy and safety for presentation at an upcoming scientific meeting and for publication in a peer-reviewed medical journal.
In 1995, Genentech, in cooperation with several breast cancer patient advocates, designed an expanded access program for severely ill breast cancer patients who have few or no other treatment options. Because of a limited supply of this investigational drug, Genentech and the breast cancer patient advocates designed a lottery system to assure an unbiased selection process. Those eligible for the expanded access program include women with tumors that overexpress HER2 and who have experienced disease progression following three or more chemotherapy regimens.
For more information, contact Genentech at http://www.herceptin.com.
Hydrazine Sulphate reverses the wasting (cachexia) caused by cancer. This drug was discovered in the 70s by Dr. Joseph Gold, a biochemist. It is inexpensive (about $20 a bottle). It works by inhibiting an enzyme in the liver from converting lactic acid into glucose. It thus prevents cancerous tumors from hogging nutrients from the body by overworking the liver. Its main purpose is to prevent the "wasting away" of the body that causes so many cancer patients to shrivel up and die. It also decreases pain.
Here is the idea. Normal cells convert oxygen and glucose into carbon dioxide and water as part of the metabolism process of their life cycles. Cancer cells, however, convert oxygen and glucose into lactic acid. The lactic acid goes to the liver which, with enormous expenditure of energy, converts the lactic acid into glucose. The glucose is further consumed by the cancer cells and converted into lactic acid. This vicious cycle robs the body of vital nutrients by putting so much of the nutrients into the lactic acid to glucose conversion process. Hydrazine Sulphate stops this process. The body stops wasting away and starts rebuilding itself as the cancer tumor shrivels into nothing.
This is a highly effective drug with absolutely proven results. Ask your doctor for the regimen to use because the dosage depends on body weight, and you CAN overdose on it. Hydrazine sulphate may be taken alone or together with other conventional or unconventional cancer therapies. Tablets are taken orally for one month, stopped for two to six weeks and then another course is begun if needed. Hydrazine sulphate is believed by supporters to work best with breast cancer, sarcomas, neuroblastoma, laryngeal cancer and Hodgkin's disease.
For more Information contact Dr. Joseph Gold Syracuse Cancer Research Institute, Presidential Plaza, 600 East Genasee Street, Syracuse, New York 13202, U.S.A., Phone: (315) 472-6616.
Hydrazine sulfate is still a legal substance, although not for cancer treatment, and it can be purchased from compounding pharmacies. One source is LifePharma, PO Box 550, Abbotsford, B.C. V2S 5Z5 Canada; OK Natural Food Distributor - PO Box 2000, Sumas, WA. 98295-2000 USA; Phone: (604) 856-0171 Fax: (604) 856-3108. They are manufacturers and distributors of Alternative Pharmaceuticals and use USP Grade Hydrazine Sulfate 30 mg and 60 mg dosages in 100-capsule bottles. Prices are $32.00 and $42.00 respectively, including Air Express shipping to anywhere on this planet. A subsidy is available to qualified patients, and discount to health professionals. They over 29000 patients using HS.
Gaston Naessens is an esoteric researcher from France who now resides in Canada. He invented a high power microscope with a unique light source which allowed him to see microorganisms which had only been seen before by Rife with his universal microscope and Rosenow with his special staining techniques a decade earlier. He also developed a compound which he dubbed 714-X for the treatment of immune related disease.
714-X is a nitrated camphor compound, which is injected intralymphatically. It is said to have a 75% success rate in treating cancer. Naessens explains its action as being taken up by the cancer cells satisfying their need for nitrogen compounds thus allowing the body these nutrients to strengthen itself. One researcher conjectured that the compound may be involved with nitric oxide mediated immunity which has is recently being elucidated.
Naessens studied a microorganism which he named the Somatid, he detailed its life cycle and correlated the health of the host to the stage of the life cycle. Very significant work. Since he was not mainstream he failed to make the connection of his organism to that of the mycoplasma. Disease associated with mycoplasma were known in the 1700's, the organisms were isolated and cultured in the late 1800's. Drawings of these organisms were published in, Pleuropneumonia-Like Organisms(PPLO) Mycoplasmataceae, by E. Klieneberger-Nobel(1962). They are remarkably similar to the drawings of Naessens because they are the same critters, though most likely different species.
You can read more about Gaston Naessens in Christopher Bird's book, The Trial and Persecution of Gaston Naessens. The work of Royal Rife is documented in, The Cancer Cure That Worked, by Barry Lynes.
714-X is licensed for export from Canada to any other country via a doctor's prescription mailed or faxed to
Related info and products available from:
Canadian Food and Drug Regulations provide for the use of an investigational drug in extenuating circumstances involving illness of a serious or life-threatening nature. Under the Emergency Drug Release Program (EDRP), a physician may request, on compassionate plea, a drug which has not been approved for either investigative human use (clinical trials) or for general marketing. In such a case, the Health Protection Branch may authorize limited quantities of the drug to be released to that physician for a specific patient.
Most physicians are reluctant to administer a product for which there is no scientific evidence to indicate possible benefit, particularly if the product is associated with dramatic overstatement of anticipated benefit. It must be clearly understood that authorization under EDRP does not imply endorsement or approval in any way of the quality, the manufacturing process or the clinical use of the product.
It is merely an authority to the drug manufacturer to supply the product to the requesting physician, thereby ensuring that the product has been provided legally. To date, no substantive information regarding 714-X has been submitted to the Health Protection Branch. The Branch does not have any medical evidence to support the claims of usefulness of 714-X in the treatment of AIDS or cancer. Its safety is unproven. At this time, the Health Protection Branch regards 714-X as an unproven product for which evidence to support treatment claims is lacking.
Antineoplaston therapy is being developed at the Burzynski Research Institute in Houston, Texas (Burzynski Research Institute). It is VERRY expensive, and it is based on urine. The following explanation of the therapy is "from the horses mouth".
"The most exciting and promising new direction of cancer research is into the body's own natural defense systems against cancer.
"Most cancer experts believe we all develop cancer hundreds if not millions of times in our lifetimes. Given the trillions of developing cells, the millions of errors that can occur in the differentiating (maturing) process of each cell, and our constant exposure to carcinogenic substances (smoke, car fumes, radiation, etc.), the laws of probability dictate that mis-developing cells must occur frequently in the life of each individual. It stands to reason that a healthy body has a corrective system to "reprogram" newly-developed cancer cells into normal differentiation pathways before the cancer can take hold.
"Cancer cells differ from healthy cells in that they are, in effect, immortal. While healthy cells live a short while and then die, cancer cells continue dividing. The program for cell death is never activated.
"Antineoplastons are peptides, small proteins and amino-acid derivatives found naturally in human blood. Cancer patients tend to have low levels -- as little as 2% that of healthy individuals. Antineoplastons work by "reprogramming" cancer cells to die like normal cells. Healthy cells are not affected.
"Antineoplastons have a two-pronged mechanism of activity. They suppress the activity of the oncogenes that cause cancer, while at the same time stimulating the activity of the tumor-suppressor genes that stop cancer.
"Antineoplastons A10 and AS2-1 seem particularly effective against brain cancer and non-hodgkins lymphoma. "
For more information contact Burzynski Research Institute, 12000 Richmond Ave., Houston TX 77082, Telephone (281) 597-0111, FAX (281) 597-1166.
For your own peace of mind, read Dr. Julian Whittakers 1996 article in Health and Healing about how antineoplastin therapy really worked to save the life of a little girl ravaged by chemo therapy, radiation, and cancer (http://catalog.com/bri/whit.htm).
Interleukin-2 is a powerful immune system stimulant and proven treatment for renal (kidney) cancer. Immunotherapy or biological therapy relies on stimulating the patient's immune response against a growing cancer, rather than giving treatments such as surgery, radiotherapy, or chemotherapy that attack the cancer directly. While several biologic agents have modest therapeutic antitumor effects, IL-2 is unique in that it is the first immunotherapy with no direct impact on cancer cells. Instead, IL-2 works indirectly to enhance host immunity, presumably by stimulating the body's T cells, white blood cells that orchestrate key immune responses, and by stimulating the production of lymphokine-activated killer (LAK) cells that can target tumors, but not normal cells.
In 1992, after reviewing the clinical trial data from 21 institutions the U.S. Food and Drug Administration approved IL-2 for the treatment of patients with advanced kidney cancer. IL-2 was the first approved drug treatment for kidney cancer in the United States.
You can get some information about the treatment from the National Kidney Cancer Association. The therapy is expensive to administer and requires doctor's care because of the toxic side effects and possibility of overdosing. One side effect is severe depression of blood Vitamin C levels often to the point of scurvy. So, you need to take a lot of Vitamin C before, during, and after treatment. IL-2 is also being used to treat lung cancer. Contact Dr. Raymond Kempf (213-226-4009) for information on clinical trials. IL-2 is not to be considered an "alternative" treatment. It has limited but definite effectiveness and is worth investigating. It is the most powerful treatment for kidney cancer.
For case histories and much more information see Steve Dunn's marvelous CancerGuide web site (http://www.cancerguide.org). Also contact Health Connection, Boston University Medical Center, Boston, MA 02118, (617) 638-6767.
For case histories and much more information see Steve Dunn's marvelous CancerGuide web site.
Harry Hoxey developed a tonic that he administered in the 1950s to cancer victims in clinics in 17 states. Thousands of patients claimed to have been healed as a result. In spite of overwhelming evidence of curing of upwards of 75,000 people, the treatment met the doom you would expect. Eventually, the US government shut his US clinics down. He opened a clinic in Tiajuana Mexico. You can get treatment programs there for less than $1000.
It all began on an Illinois horse farm in 1840. Harry's great grandfather John Hoxsey was a veterinarian whose prize stallion got cancer. He put it out to pasture to die, but three weeks later the tumor had stabilized. He observed the horse eating unusual plants not part of its normal diet. Within a year the horse was well.
John Hoxsey began to experiment on animals with the herbs, and he added other popular home remedies. He claimed success and passed the formulas down through the family. Hoxsey said his father was the first to try the medicines on people. He gave young Harry the formulas with a death bed wish to make the treatment available to people whether or not they could pay. He insisted it carry the Hoxsey name and warned the boy against the high priests of medicine.
Harry Hoxsey started his first clinic in 1924 in Illinois and he immediately incurred the wrath of organized medicine. A non-toxic herbal remedy, a nutritional program, and an attitudinal approach to healing, harmless though it seems, ignited one of the most bitter controversies in medical history. It started a cancer war between organized medicine and one man, founder Harry Hoxsey, the ex-coal miner with an 8th grade education.
In 1937 Harry demonstrated the workability of the formula to Chicago members of the AMA who then offered to buy it. Harry refused to sell it to them because they refused to give treatments free to those who could not afford to pay. To get even, Fishbein, editor of the AMA journal, denied the workability of the formula and labeled Harry a "quack". Harry sued him and the AMA for slander and won by proving the tonic worked. The trial revealed that Fishbein had failed anatomy in medical school, never finished residency, and had never treated a patient.
The ingredients of the Hoxsey tonic are not publicly available from Hoxsey himself. However, AMA Laboratories analyzed the Hoxsey Tonic and reported their findings in the Journal of The American Medical Association in its issue of June 12, 1954:
Each 5cc of the Hoxsey Tonic contains:
Potassium Iodide.......... 150 Mg 7.7% Licorice ................. 20 Mg 7.7% Red Clover ............... 20 Mg 7.7% Burdock Root ............. 10 Mg 3.8% Stillingia Root........... 10 Mg 3.8% Berberis Root............. 10 Mg 3.8% Poke Root ................ 10 Mg 3.8% Cascara Amarga ........... 5 Mg 1.9% Prickly Ash Bark ......... 5 Mg 1.9% Buckthorn Bark ........... 20 Mg 7.7% Maximum dose: 1 teaspoonful 4 times per day.
Hoxsey Tablets #100 (black)1 which is essentially
the same as the liquid:
Potassium Iodide.......... 75 mg Licorice.................. 10 mg Red Clover................ 10 mg Burdock Root.............. 5 mg Stillingia Root........... 5 mg Berberis(barberry) root... 5 mg Poke root................. 5 mg Cascara Segrada......... 2.5 mg Prickly Ash Bark.......... 2.5 mg Buckthorn bark............ 2.5 mg
Max dose: 2 tablets 4 times a day.
Lactaba Red: Same as the #100 tablets, plus 1/10 mg pepsin, but without the licorice, burdock root, and cascara1:
Cal-Ton tablets (Yellow): Same as #100 tablets, but with 4.85 grains of iodized lime substituted for potassium Iodide(1).
Sixteen additional Hoxsey formulas are available for researchers and doctors from The Arlin J. Brown Information Centre, PO Box 251, Fort Belvoir, Virginia 22060, ph 1-703-752-9511.
The following is from "Whats In the Hoxsey Treatment?" By E. Edgar Bond, B.L.M.D., Editor of the Journal of Medical Physical Research. reprinted from the January, 1961, National Health Federation Bulletin, also the Journal of The American Medical Association in its issue of June 12, 1954, of its "investigation" into the Hoxsey Cancer Clinic, Dallas, Texas.
According to the article the Hoxsey tonic contains these crude drugs:
POTASSIUM IODIDE RED CLOVER (Trifolium Pratense) BURDOCK ROOT (Arctium Lappa, Lappa Major) Roots or Seeds CASCARA AMARGA (Honduras Bark, Picramaia, etc) PRICKLY ASH (Xanthoxylum Flaxineum) POKE BERRIES (Phytolacca Decandra) STILLINGIA (Sylvatica) BUCKTHORN (Rhamnus Frangula) LICORICE (Glycyrrhiza Glabra)
All foods that produce uric acid should be avoided, as much as possible. Those who follow a diet, during treatment, similar to that followed by vegetarians appear to recover faster and better. The diet used with the Koch treatment is also very good, according to the experience of patients reporting to us.
The foregoing remedy is an alterative and topic. It should be used as an adjutant to a doctor's regular procedure. It should not be called a cancer cure, but rather an aid to normalcy.
If any of the following symptoms develop and are too severe, discontinue medication until symptoms are gone (usually in two or three days). Then resume with one-half original dosage and gradually increase dosage to an amount most comfortably tolerate and then continue.
Pimples appear on face, shoulders and forehead, as well as other locations on the body. They may become boil like. Glands in the neck may swell, as well as the area of trouble.
Excessive watering of the eyes and nose may occur particularly when bending over. Nausea and vomiting may develop. A bitter or salty taste may upset the appetite and an extreme feeling of weakness, particularly in the knees, may occur, as well as a pounding, rapid heartbeat.
These symptoms seldom occur but are given here as a guide to the doctor in caring for his patient.
Detoxification and rebuilding of the body has also produced remarkable recoveries from heart conditions, arthritis, bursitis, sciatica, and similar ailments.
Patients who have had Pap tests indicating the necessity of an immediate radical hysterectomy have been cleaned up in 30 to 60 days.
Lumps, biopsied as cancer, in the breast area or other parts of the lymph system have become so isolated or atrophied, after detoxification courses, that often no surgery is necessary, or, when surgery is still advisable, simple rather than radical operations are required.
Contact Information For The Hoxsey Clinic:
The Biomedical Center (Hoxsey Clinic), Mildred Nelson, PO Box 727, Tijuana, B.C., Mexico (Actual address is 611 General Ferreira Ave), US Phone: 706-684-9011. Please do not call her in the middle of the night! Or write to Mildred Nelson c/o John Meyers, PO Box 3654, San Ysidro, California, 92073, USA.
Office hours are 9am-4pm, closed on weekends and US/Mexico holidays,
The cost of the treatment is about $500 (it may be more now) including 4 weeks room and board (outpatients only). The program is under the direction of medical doctors. A "simplified Gerson-like" dietary cancer therapy is now available, including selected minerals, trace minerals, specially processed cell foods etc. complete recovery has been accomplished in a few weeks, but may take months, depending on the degree of body malfunction at the start of therapy.
The Hoxsey Clinic also uses Koch's Glyoxylide, Gaston Nassen's 714X, Rife's radio therapy etc, as part of their healing modality.
The Video "Hoxsey Quack who Cures Cancer" (82 mins) is highly recommended viewing and is available from Realdad Productions (US $55+$15 shipping), PO box 1644, Santa Fe, New Mexico 87504 Ph: (0011-1) 505 989-8575 Fax: 505 983- 8957. Also available from Realdad is the Bernie Siegal film "Hope and a Prayer" ($40).
By Matti Narkia, Helsinki, Finland
Fever therapy, which has helped to stop or slow down the advancement of my disease is an American invention, which in the latter part of this century has mainly been practiced in Europe. Because of recent inquiries, and to pay tribute to the great American doctor who invented this therapy, I did some homework and collected information about fever therapy from the books of three American authors into a concise summary. The information includes data up to 1991, I have no knowledge of what, if anything, has happened in this area since then.
I have included contact information of some clinics which include fever therapy in their cancer program. Some of this data may have changed. I obtained this information from the books mentioned, I have no knowledge of the quality of the medical services offered and therefore cannot endorse any of them. If you have any further information - positive or (especially) negative - of the quality of the services, success rate etc.., of these clinics, I would greatly appreciate it if you mailed me a comment.
In 1888, Dr. William B. Coley (1862-1936), Harvard Medical School graduate, and eminent New York City surgeon and Sloan-Kettering researcher, stumbled across one of the most intriguing findings ever made in cancer research. In fact, his invention was a starting point for all modern immunotherapy. His discovery was first tolerated, then ridiculed, and finally suppressed, although in recent years some new interest in his discovery has emerged among researchers.
Frustrated after losing his first patient at Memorial Hospital, a 19 year old female bone cancer patient, despite an early detection followed by prompt amputation of her arm and a good prognosis, Coley began methodically searching the patient records at New York Hospital . He went back 15 years and examined records of all bone cancer patients. Most cases ended in failure and death. To his amazament, however, Coley discovered one patient who had been given up for lost by his doctors and yet had walked out of the hospital in apparently perfect health . On his deathbed, this patient had suffered two attacks of erysipelas, a severe skin infection caused by bacteria Streptococcus pyogenes.
Coley's first attempts to produce reaction in cancer patients by injecting streptococcus cultures into them ended in failure. Luckily, he managed to get a particularly virulent culture from a famous German bacteriologist, Robert Koch, through a friend. The patient who received this culture developed a severe case of erysipelas with high fever. Within a few days the tumors on his tonsils and neck completely disappeared. In 1893 Coley published his first paper on the new method .
Because using live bacteria was dangerous and caused an ordeal for the patient, Coley later tried to and succeeded in improving his method. Instead of using bacteria, he mixed the toxins of the strep with those of another germ, Bacillus prodigiosus, which today is called Serratia marcesens. This seemed to work similarly to the live culture.
Best results were obtained when Dr. Coley or his colleague supervised the production of toxins. Parke-Davis, the pharmaceutical company, also produced the toxins commercially for many years, but they heated the formula, which reduced its effectiviness. Despite that, even this weakened form of toxins, Parke-Davis formula #IX, showed 37 percent cure rate for inoperable patients.
In 1943 NCI researcher M.J. Shears discovered that the biologically active substance in Coley's toxins is lipopolysaccharide (LPS), which occurs in the cell walls of gram-negative bacteria .
By 1953, however, all the production of the toxins in the United States stopped.
For over 30 years starting late 50s or early 60s, Dr. France Havas, professor emeritus of the Department of Microbiology and Immunology at Temple University School of Medicine, Philadelphia, studied the effects of Coley's toxins in mice and humans. The results of her studies were generally favorable, even in advanced patients [5,6,7,8].
In 1976 randomized trials of mixed bacterial vaccines (MBV) - as Coley's toxins are now called - begun at Memorial Sloan-Kettering.
In 1991 K.F.Kolmel and colleagues in Gottingen, Germany reported on favorable results obtained on treatment of advanced melanoma with Coley's toxins .
Recently Coley's toxins have been researched and used also in China. Zhao and others published 1991 preliminary results of these trials .
Coley's results have been tabulated by his daughter, Helen Coley Nauts, D.Sc., former executive director of the Cancer Research Institute, Inc., in New York City . She and her medical colleagues have documented 894 cases treated with Coley's vaccine. Examples:
Tumor type # of operable Alive after # of inoper. Alive after patients 5 years patients 5 years Giant cell bone tumor 38 33 (87%) 19 15 (79%) Breast cancer 13 13 (100%) 20 13 (65%)
Other 5-year survival rates: 67% in Hodgkin's disease, 67% in inoperable ovarian cancer, 60% in inoperable malignant melanoma. Overall, patients with inoperable tumor of various kinds had 45% 5-year survival, while those with operable tumors had 50%.
In 1962, Dr. Barbara Johnston, M.D. published a double blind study on Coley's toxins. This study was conducted at New York University-Bellevue Hospital. The results were clear-cut. In the control group treated with fever inducing placebo, only one patient of 37 showed any signs of improvement. Of the 34 patients treated with Coley's toxins, 18 showed no improvement, 7 noted decreased pain while 9 showed such benefits as tumor necrosis, apparent inhibition of metastases, shrinkage of lymph nodes, and disappearance of tumors .
In 1982 at the conference held in Cologne, Germany, Mrs. Nauts reported the first results of randomized trials of MBV (Coley's toxins) begun in 1976 at Memorial Sloan-Kettering: Advanced non-Hodgkin's lymphoma patients receiving MBV had a 93 percent remission rate as opposed to 29 percent for controls who received chemotherapy alone .
 Cancer Research Institute. Review of Progress and Hope. New York 1976.
 Coley, William B. "A Preliminary Note on the Treatment of Inoperable Sarcoma by the Toxic Product of Erysipelas." Post-graduate 8:278-86, 1893.
 Coley, William B. "The Cancer Symposium at Lake Mohonk." American Journal of Surgery (New Series) 1:222-25, October 1926.
 Ward, Patricia Spain. Memo to John Gibbons. December 2 1988.
 Havas H, et al. Mixed bacterial toxins in the treatment of tumors. I. Methods of preparation and effects on normal or Sarcoma 37-bearing mice. Cancer Res. 1958;18:141-148.
 Havas H, et al. Mixed bacterial toxins in the treatment of tumors. III. Effect of tumor removal on the toxicity and mortality rates in mice. Cancer Res. 1960;20:393-396
 Havas H, and Donnelly A. Mixed bacterial toxins in the treatment of tumors. IV. Response of methylcholanthrene-induced, spontaneous, and transplanted tumors in mice. Cancer Res. 1961;21:17-25.
 Havas H, et al. The effect of bacterial vaccine on tumors and immune response of ICR/Ha mice. J Biol Res Mod. 1990;9;:194-204.
 Kolmel K, et al. Treatment of advanced malignant melanoma by a pyrogenic bacterial lysate. A pilot study. Onkologie. 1991;14:411-417.
 Zhao YT, et al. Preliminary reult of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol & Tumor Pharmacother. 1991;8:23-28.
 Nauts, Helen Coley. Immunotherapy of Cancer by Bacterial Vaccines. Paper read at International Symposium on Detection and Prevention of Cancer. New York, April 25 - May 1, 1976.
 Johnston, Barbara, "Clinical Effects of Coley's Toxin. 1. Controlled Study. 2. A Seven-Year Study." Cancer Chemotherapy Reports 21:19-68, August 1962.
 Nauts, Helen Coley, Bacterial Products in the Treatment of Cancer: Past, Present and Future. Paper read at the International Colloqium on Bacteriology and Cancer, Clogne, Federal Republic of Germany, March 16-18, 1982.
 Nauts, Helen Coley, Bacterial vaccine therapy of cancer. Dev Biol Stand. 1977;38487-94.
 Nauts, Helen Coley, Bacterial pyrogens: bemeficial effect on cancer patients. Prog Clin Biol Res. 1982;107:687-96.
 Nauts, Helen Cole, Bacteraia and cancer - antagonisms and benefits, Cancer Surv. 1989;8:713-23.
 Keen AR and Frelick RW, Response of tumors to thermodynamic stimulation of the immune system. Del Med J. 1990;62:1115-6.
 Cunningham RS and Pearson FC. ImuVert activation of natural killer cytotoxicity and interferon gamma production via CD16 triggering. Int J Immunopharmacol. 1990;12:589-98.
 Jimenez JJ et al. Treatment with ImuVert aborts development of chloroleukemia in newborn rats. J Biol Response Mod. 1990;9:300-4.
 Cress NB, et al. ImuVert therapy in the treatment of recurrent malignant astrocytomas: nursing implications. J Neorosci. Nurs. 1991;23:29-33.
 Jaeckle KA, et al. Phase II trial of Serratia marcesenses extract in recurrent malignant astrocytoma. J Clin Oncol. 1990;8:1408-18.
 Abe H. [antitumor effect of LPS immobilized beads]. Nippon Geka Gakkai Zasshi. 1991;92:627-35.
For treatment contact Waisbren Clinic:
Burton A. Waisbren Sr., MD, FACP
2315 North Lake Drive
Room 815, Seton Tower
Milwaukee, Wisconsin 53211
For information contact:
Cancer Research Institute
681 Fifth Avenue
New York, NY 10022
Phone: 800-223-7874, in New York 800-522-5022
Mrs. Nauts, who is the director of communications for CRI, can be reached at 1225 Park Avenue, New York, NY 10128, phone: 212-722-8547.
Klaus F. Kolmel, Priv. Doz. Med.
von Sieboldstrasse 3
3400 Gottingen, Germany
Phone: +49-551-396-081. Fax: +49-551-396-092
Phone: +86-1-868-401. Dr. Guo Zheren, MD.
A pioneer in alternative cancer treatment, Josef Issels, MD, of Germany, achieved remarkable remissions, even in advanced cases, through combination of therapies designed to shrink the tumor and repair the body's defense mechanisms. His "whole body" approach included anticancer vaccines, an anticancer diet emphasizing organic raw foods, and fever therapy to stimulate immune function. He also used a variety of methods to rebuild the immune system and change the body's biochemistry to eliminate an evironment favorable for the development of cancer.
Occasionally he also used very-low-dose chemotherapy, surgery, radiation and ozone therapy in combination with immunotherapy. He prescribed organ extracts to repair damage to organs and improve their functioning. He also administered organ-specific RNA and DNA, proteolytic enzymes to destroy the protein coat surrounding tumors, as well as vitamins and minerals to strengthen the body's enzyme activity. He recommended his patients to have the infected teeth and/or tonsils, and metallic (especially mercury amalgam) fillings removed, because he felt these could have unfavorable effect on immune system. His program also includes psychotherapy to deal with the emotional factors that he felt could hinder recovery.
Dr. Issels gave patients a "fever shot" once a month to raise the body temperature as high as 105 F. He induced active fever with the ethical drug Pyrifer, made from specially treated coli bacteria. He induced passive fever by means of hyperthermia: the patient was placed inside a cylinder containing electrodes that bombarded his or her body with ultra short waves.
He tried to motivate the cancer patients to take on full time struggle against cancer. As one unusual example, his cancer patients were routed out of their beds to do light mountain climbing in the Bavarian Alps. The patients also participated in a daily exercise that included jogging.
Two independent studies - one at King's college Hospital in London, the other at the University of Leyden in Holland - confirmed that about 17 percent of Issel's terminal patients led normal, cancer-free lives for at least five years. Their life expectancy upon admission had been less than one year.
In 50s and 60s the German medical establishment was nowhere near as liberal as now. It boycotted and isolated Dr. Issels. Finally, the German medical authorities leveled trumped-up charges of fraud and manslaughter against Issels, and in 1960, Issels was imprisoned in a cell block containing only convicted murderers. Eventually, however, Dr. Issels was acquitted of all charges.
Dr. Issels is now living in retirement in Florida. A "multimodality immunotherapy program" based on his method is offered by Ahmed Elkadi, MD, and colleagues at the Panama City Clinic in Panama City, Florida. Another current practitioner of the Issels methods is Dr. Wolfgang Woeppel at the Hufeland Klinik in Bad Mergentheim, Germany.
 Issels, Josef, Cancer: A Second Opinion. London 1975.
 Issels, Josef, "Cancer - Whole-body Approach and Immunotherapy," lecture given in New York, 1980.
Akbar Clinic (Panama City Clinic)
Ahmed Elkadi, MD
236 South Tyndall Parkway
Panama City, FL 32404
Phone: (904) 763-7689. Fax: (904) 763-5396
Hufeland Klinik for Holistic
Wolgang Woeppel, MD
D-6990 Bad Mergentheim
Phone: +49-7931-8185 or +49-7931-7082
Professor Dr. Albert Landsberger
D-7829 Friedeweiler 2, Germany
Phone: 07651 208-0 Fax: 07651 208-116
Veramed Klinik am Wendelstein
D-8204 Brannenburg/Obb., Germany
Phone: 08034/3020 or 08034/302750
Information on fever therapy and other noninvasive therapies is available from:
Foundation for Advancement in Cancer Therapy (FACT)
Old Chelsea Station
New York, NY 10113
Phone: (212) 741-2790
Contact person: Ruth Sackman.
"This is a dramatic breakthrough in the treatment of CML. Someday, the specific targeting we've proven can work for CML will be used for other cancers. Behind every successful research project, there's a dream of what might be. That inspiration is what sustains you through the years of hard work."
October 7, 2000-Quote by Doctor Brian Druker, Primary Investigator of Glivec (STI571), Associate Professor of Medicine (Hematology and Medical Oncology), Oregon Health Sciences University, Portland, Oregon.
"STI571 is a dramatically active cancer drug, perhaps the most impressive drug that I have seen in 20 years as an Oncologist. It has fulfilled all of its promises." August 14, 2000-Quote by Doctor Moshe Talpaz, Professor of Medicine and Chairman of the Department of Bioimmunotherapy, M. D. Anderson Cancer Center, Houston, Texas. Doctor Talpaz is one of the Worlds leading authorities on leukemia and its treatment.
Glivec (STI571) is manufactured by Novartis, currently the second largest drug company in the World, headquartered in Basel, Switzerland. It was officially named "Glivec" on November 30, 2000 and was previously called STI571 or CGP57148B and there are many articles using these designations in the literature. Glivec (STI571) is on the "Fast Track" approval schedule at the F.D.A. (United States Food and Drug Administration). Glivec was submitted to the F.D.A for approval on February 27, 2001. By law, drugs on the "Fast Track" have to be approved or rejected within 6 months of submission so this means that F.D.A. approval will come within 6 months. Other countries have different approval processes. To date, no country has approved Glivec for prescription sale.
Glivec (STI571) is the first of a new class of antiproliferative agents called signal transduction inhibitors, which interfere with the pathways that signal the growth of tumor cells. Glivec (STI571) is targeted to the specific biochemical abnormality found predominantly in a form of leukemia called chronic myeloid leukemia (CML). Glivec (STI571) kills the abnormal cells while having little effect on normal cell growth. Laboratory studies have shown that Glivec also inhibits an enzyme called C-Kit which is present in a relatively rare form of cancer called GIST (Gastro Intestinal Stromal Tumor). There are some small trials being conducted on GIST tumors in the U. S. A. with plans to expand those trials to other countries. It is too early to reach any valid scientific conclusions with GIST, however, early data looks very promising.
As Judy Orem has said, drugs don't just pop off the shelves. As is the case with any drug, there is a long process before a drug reaches the stage where STI 571 has arrived. In the case of STI 571, the research effort at began at Ciba-Geigy (now Novartis) in the early 1990s. Finding a compound that works in research models is the first stage in identifying a candidate drug. The next stage, which is referred to as pre-clinical development, involves a team of individuals who perform the work required prior to human clinical testing. This time consuming phase involved a dedicated team of development scientists who studied the synthesis, toxicology, metabolism, formulation and production of the final drug. In the case of STI 571, there are several scientists who deserve particular mention. These include: Juerg Zimmermann, the chemist who synthesized STI 571, Elizabeth Buchdunger, a scientist at Novartis who did much of the original cellular profiling of STI 571 and related compounds and Helmut Mett, who was responsible for enzymology. Peter Graff, Ulrika Pfaar and Hans Michael Buerger also deserve special mention for their contribution to the success of the pre-clinical development phase of STI 571. In addition to these scientists, this project could not have progressed without the continual support of Alex Matter, who is the director of the Oncology Research unit at Novartis that discovered STI 571. Lastly, and most importantly, is Nicholas Lydon. Nick was the person in charge of the kinase inhibitor program from which STI 571 was created and Nick was the person who sent me a number of Abl kinase inhibitors, including STI 571, to test in the lab.
When I demonstrated that STI 571 had remarkable activity and specificity for CML, Nick immediately recognized the promise of this compound and is responsible for seeing STI 571 through the research and pre-clinical developmental phases. Nick and I spent countless hours discussing all of the issues required to get STI 571 to its current status, but when all was said and done, Nick actually got things done. Currently, Nick has set up his own company, Kinetix Pharmaceuticals Inc., based out of Medford, MA, to develop other kinase inhibitors, like STI 571. We owe all of these unsung heroes a debt of gratitude.
The media has dubbed STI 571, the leukemia pill. Although there are many things about STI 571 to celebrate, the media has certainly captured one of the most appealing aspects of STI 571, that is, its ease of administration. No infusions, no injections, just a pill to get rid of leukemia.
It sounds simple, but it is no accident that STI 571 is a pill. In fact, the first form of STI 571 developed was intended for intravenous infusion. In one of our many discussions about the development of STI 571, Nick Lydon and I talked about how STI 571 would be given. That is, would it be given every other week, one week of every month, or daily and for how long. It was my view that STI 571 would probably have to be given daily for long periods of time. Nick immediately recognized that for patient convenience, STI 571 should be in pill form and I agreed. Nick then put his Novartis STI 571 team up to the challenge of modifying STI 571 so that it could be formulated into a pill. The rest, as they say, is history.
You are visitor # [an error occurred while processing this directive].